HC Wainwright Has Positive Estimate for BCRX FY2025 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Stock analysts at HC Wainwright increased their FY2025 earnings estimates for BioCryst Pharmaceuticals in a research note issued to investors on Tuesday, November 4th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will post earnings of $0.09 per share for the year, up from their prior estimate of $0.06. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, November 3rd. The biotechnology company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.01). The firm had revenue of $159.40 million during the quarter, compared to analyst estimates of $162.91 million. BioCryst Pharmaceuticals’s quarterly revenue was up 36.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.07) earnings per share. BioCryst Pharmaceuticals has set its FY 2025 guidance at EPS.

Several other analysts also recently issued reports on BCRX. Evercore ISI reaffirmed an “in-line” rating and issued a $8.00 price target on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of BioCryst Pharmaceuticals in a research report on Wednesday, October 8th. TD Cowen assumed coverage on BioCryst Pharmaceuticals in a report on Wednesday, October 15th. They issued a “buy” rating and a $30.00 price target for the company. Citizens Jmp reduced their target price on shares of BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating on the stock in a report on Wednesday. Finally, Cantor Fitzgerald lifted their price target on shares of BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the stock an “overweight” rating in a report on Wednesday, October 15th. Ten research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $19.33.

BioCryst Pharmaceuticals Stock Down 2.0%

NASDAQ:BCRX opened at $7.03 on Friday. BioCryst Pharmaceuticals has a 52-week low of $6.00 and a 52-week high of $11.31. The stock has a fifty day simple moving average of $7.47 and a 200-day simple moving average of $8.67. The company has a market capitalization of $1.48 billion, a PE ratio of -39.05 and a beta of 1.09.

Insider Buying and Selling

In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of the stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total transaction of $595,700.00. Following the transaction, the director owned 65,352 shares of the company’s stock, valued at $556,145.52. This trade represents a 51.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BCRX. State Street Corp increased its stake in BioCryst Pharmaceuticals by 8.9% during the second quarter. State Street Corp now owns 8,505,392 shares of the biotechnology company’s stock worth $76,208,000 after acquiring an additional 691,988 shares during the last quarter. Alkeon Capital Management LLC increased its position in BioCryst Pharmaceuticals by 1.7% during the 1st quarter. Alkeon Capital Management LLC now owns 7,214,021 shares of the biotechnology company’s stock worth $54,105,000 after purchasing an additional 120,199 shares in the last quarter. Geode Capital Management LLC raised its holdings in BioCryst Pharmaceuticals by 1.9% in the second quarter. Geode Capital Management LLC now owns 5,054,610 shares of the biotechnology company’s stock valued at $45,296,000 after buying an additional 93,973 shares during the period. Arrowstreet Capital Limited Partnership lifted its position in BioCryst Pharmaceuticals by 2,103.7% during the second quarter. Arrowstreet Capital Limited Partnership now owns 4,278,555 shares of the biotechnology company’s stock valued at $38,336,000 after buying an additional 4,084,403 shares in the last quarter. Finally, Millennium Management LLC grew its stake in BioCryst Pharmaceuticals by 382.6% during the first quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company’s stock worth $28,597,000 after buying an additional 3,022,769 shares during the period. Institutional investors and hedge funds own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.